CYRAMZA therapy necessitates vigilant monitoring and specific precautions to mitigate serious adverse events.

Precautions and Monitoring

CYRAMZA increases the risk of hemorrhage, gastrointestinal perforation, impaired wound healing, arterial thromboembolic events, hypertension, infusion-related reactions, hepatic impairment, posterior reversible encephalopathy syndrome, proteinuria, and thyroid dysfunction. Blood pressure, urine protein, and thyroid function should be regularly monitored. The drug should be withheld before elective surgery and not resumed until adequate wound healing is confirmed. Permanent discontinuation is required for severe or unmanageable adverse reactions such as grade 3/4 hemorrhage, gastrointestinal perforation, or hypertensive crisis. Embryo-fetal toxicity is a concern; effective contraception is advised.